PBA
CYTK icon

Paradigm Biocapital Advisors’s Cytokinetics CYTK Stock Holding History

Paradigm Biocapital Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,480,857
Closed -$97.6M – 32
2026
Q1 		$97.6M Buy
+1,480,857
New +$94.1M 1.99% 17
2025
Q2 		– Sell
-858,664
Closed -$34.5M – 31
2025
Q1 		$34.5M Buy
+858,664
New +$39.5M 1.58% 16

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paradigm Biocapital Advisors's CYTK Position: Q2 2026 in Review

Paradigm Biocapital Advisors sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 1,480,857 shares — an estimated $97.6M sold.

Paradigm Biocapital Advisors first reported a position in CYTK in Q1 2025 and held it in 2 quarters. The position peaked at $97.6M in Q1 2026. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Paradigm Biocapital Advisors reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,480,857 Cytokinetics shares in Q2 2026, an estimated $97.6M.
  • Paradigm Biocapital Advisors first reported a position in Cytokinetics in Q1 2025 and held it in 2 quarters.
  • Paradigm Biocapital Advisors's Cytokinetics position peaked at $97.6M in Q1 2026.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.